Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies

Next Previous
Trial Profile

A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BR-101801 (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Marginal zone B-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Boryung Pharmaceutical

Most Recent Events

  • 21 Feb 2024 Status changed from recruiting to active, no longer recruiting.
  • 12 Dec 2023 Results (As of Jul 19, 2023, n=26) presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 06 Jun 2023 Results(n=12) for the phase 1a study assessing the safety, efficacy and pharmacokinetic characteristics of BR101801 in adult patients with advanced hematologic malignancies presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top